The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 35 | — | 20.1x | Near average | |
Growth | 29 | — | 5.6% | Below average | |
Quality | 33 | -125.4% | 7.6% | Below average | |
Safety | 50 | 0.1x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | 46 | — | — | Near average | |
Sentiment | 34 | — | — | Below average |
Pyxis Oncology, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Pyxis Oncology, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Pyxis Oncology stock experienced a notable decline in its average price target by 13.11% over the past week, dropping from 6.33 dollars to 5.5 dollars, despite new analysts joining the coverage. This bearish adjustment in expectations reflects a re-evaluation of fair value by the five current analysts, with a relatively narrow dispersion range between 5 and 6 dollars, indicating a consensus on the expected growth ceiling in the near term.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.